






1




2




3




4



5




6




7

<b>Rhythmusstörungen mit Potential für "Heilung"</b>	
○ AVNRT	<b>95-98%</b>
○ WPW	<b>90-95%</b>
○ Typisches Vorhofflimmern	<b>&gt;90%</b>
○ Idiopathische VES	<b>80-90%</b>
<ul style="list-style-type: none"> <li>➤ Komplikationsrisiko: 1% Leiste, &lt;1% Tamponade</li> <li>➤ Medikamentöse Therapie: Wenig effektiv, NW</li> </ul>	


8




9




10




11




12



13




14




15




16




17



18




19



20




21



22




23



24

<b>Vorhofflimmern Ablation – Eigene Erfahrung</b>	
<b>VHF Ablationen (seit Okt 2021): 530</b>	
Perikarderguss	2 (0.4%)
Leistenkomplikation	2 (0.4%)
Dekompensation	1 (0.2%)
Phrenikusparese (transient)	6 (1.1%)

25



26

<b>Pulsed-field ablation of Atrial Fibrillation</b>				
Event	Serious Adverse Events <sup>a</sup>		Serious or Nonserious Adverse Events <sup>b</sup>	
	Pulsed Field Ablation (N = 305)	Thermal Ablation (N = 302)	Pulsed Field Ablation (N = 305)	Thermal Ablation (N = 302)
number of patients (percent)				
Any event	6 (2.0)	4 (1.3)	7 (2.3)	6 (2.0)
Death	1 (0.3)	0	1 (0.3)	0
Myocardial infarction	0	0	0	0
Persistent phrenic-nerve palsy	0	0	0	2 (0.7)
Stroke	0	1 (0.3)	0	1 (0.3)
TIA	1 (0.3)	0	1 (0.3)	0
Systemic thromboembolism	0	0	0	0
Cardiac tamponade or perforation	2 (0.7)	0	2 (0.7)	0
Percarditis	1 (0.3)	0	2 (0.7)	0
Pulmonary edema	1 (0.3)	1 (0.3)	1 (0.3)	1 (0.3)
Vascular-access complication	1 (0.3)	2 (0.7)	1 (0.3)	2 (0.7)
Heart block	0	0	0	0
Gastric motility or pyloric spasm	0	0	0	0
Pulmonary vein stenosis	0	0	0	0
Atrioesophageal fistula	0	0	0	0

27


**Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation**

Christian Sohns, M.D., Henrik Fox, M.D., Nassir F. Marrouche, M.D., Harry J.G.M. Crijns, M.D., Ph.D., Angelika Costard-Jaeckle, M.D., Leonard Bergau, M.D., Gerhard Hindricks, M.D., Nikolaos Dagres, M.D., Samuel Sossalla, M.D., Rene Schramm, M.D., Ph.D., Thomas Fink, M.D., Mustapha El Hamriti, M.D., Maximilian Moersdorf, M.D., Vanessa Sciacca, M.D., Frank Konietzschke, Ph.D., Volker Rudolph, M.D., Jan Gummert, M.D., Jan G.P. Tijssen, Ph.D., and Philipp Sommer, M.D., for the CASTLE HTx Investigators


The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


28



29



30



31